市場調查報告書
商品編碼
964863

亞太地區的膀胱癌治療及診斷市場-成長,趨勢,及預測(2020年∼2025年)

Asia-Pacific Bladder Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 78 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

隨著膀胱癌患者人數的增加和新的診斷和治療方法的引入,在預測期內,亞太膀胱癌治療和診斷市場的規模預計將以5%的複合年增長率增長。2018年,日本登記了大約37,293例新的膀胱癌病例,導致約9,943人死亡。這表明需要早期治療和診斷。另外,正在開發用於治療膀胱癌的新藥。這些因素有望推動市場增長。

本報告提供亞太地區的膀胱癌治療及診斷市場調查,提供市場概要,市場成長要素及阻礙因素分析,各類型·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介,市場機會等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場推動因素
    • 膀胱癌的負擔增加
    • 醫藥品開發的創新
  • 市場阻礙因素
    • 學名藥的使用增加
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 治療學
    • 診斷
  • 各癌症類型
    • 上皮移行癌
    • 鱗狀上皮癌
    • 其他
  • 各地區
    • 亞太地區

第6章 競爭情形

  • 企業簡介
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Eli Lilly & Company
    • Endo Pharmaceuticals Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline
    • Novartis
    • Pfizer
    • Sanofi
    • Johnson & Johnson

第7章 市場機會及趨勢

目錄
Product Code: 46473

Asia-Pacific Bladder Cancer Therapeutics and Diagnostics market is expected to register a CAGR of 5% during the forecast period, owing to increasing burden of bladder cancer and new diagnosis & treatments coming up in the market. According to Globocan, 2018, around 37,293 new cases of bladder cancer were registered in Japan and around 9,943 deaths occurred due to it. This calls for the need of early treatment and diagnosis. Furthermore, new drugs are being developed for the treatment of bladder cancer. In 2020, BeiGene Ltd., recieved an approval from China National Medical Products Administration (NMPA) for anti-PD-1 antibody tislelizumab in the treatment of locally advanced or metastatic urothelial carcinoma (UC). Hence, these factors are expected to drive the growth of the market.

Key Market Trends

Bladder Ultrasound is Expected to Show a Steady Growth During the Forecast Period

Bladder Ultrasound is one of the type of diagnostic device which uses sound waves to detect and analyze the cancer present in the bladder. The growing incidence of bladder cancer and new devices are being developed for the diagnosis of cancer are expected to stimulate the growth in this segment. According to the Globocan, 2018, almost 4,249 incidences of bladder cancer were observed in the Korea Republic of with around 1,712 deaths. Ultrasound is the most common method used in diagnosing the early stages of cancer due to its specificity. Hence, it is expected to boost the demand for ultrasound devices in the market during the forecast period.

Competitive Landscape

Some of the key players in the market are AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Endo Pharmaceuticals Inc. and Johnson & Johnson. Companies are constantly indulged in developing the products related to diagnosis and treatment of the bladder cancer to grow their presence in the market. In 2018, Merck recieved an approval from Japanese Ministry of Health, Labor and Welfare (MHLW) for it's product Keytruda (MSD) which is used for the treatment of urothelial cancer patients.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Bladder Cancer
    • 4.2.2 Innovation in Drug Development
  • 4.3 Market Restraints
    • 4.3.1 Increased Used of Generic Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 By Therapeutics
      • 5.1.1.1 Chemotherapy
      • 5.1.1.2 Immunotherapy
      • 5.1.1.3 Others
    • 5.1.2 By Diagnostics
      • 5.1.2.1 Cystoscopy
      • 5.1.2.2 Bladder Ultrasound
      • 5.1.2.3 Urinalysis
      • 5.1.2.4 Others
  • 5.2 By Cancer Type
    • 5.2.1 Transitional Cell Bladder Cancer
    • 5.2.2 Squamous Cell Bladder Cancer
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 Asia-Pacific
      • 5.3.1.1 China
      • 5.3.1.2 Japan
      • 5.3.1.3 India
      • 5.3.1.4 Australia
      • 5.3.1.5 South Korea
      • 5.3.1.6 Rest of Asia-Pacific

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca Plc
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eli Lilly & Company
    • 6.1.4 Endo Pharmaceuticals Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 GlaxoSmithKline
    • 6.1.7 Novartis
    • 6.1.8 Pfizer
    • 6.1.9 Sanofi
    • 6.1.10 Johnson & Johnson

7 MARKET OPPORTUNITIES AND FUTURE TRENDS